Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2021; 12(9): 1426-1441
Published online Sep 15, 2021. doi: 10.4239/wjd.v12.i9.1426
Dipeptidyl peptidase-4 inhibitor-induced autoimmune diseases: Current evidence
Ayan Roy, Jayaprakash Sahoo, Niya Narayanan, Chandhana Merugu, Sadishkumar Kamalanathan, Dukhabandhu Naik
Ayan Roy, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Jodhpur 342005, India
Ayan Roy, Jayaprakash Sahoo, Niya Narayanan, Chandhana Merugu, Sadishkumar Kamalanathan, Dukhabandhu Naik, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006, India
Author contributions: Sahoo J and Kamalanathan S conceptualized the work; Roy A wrote the first draft and provided critical inputs; Narayanan N and Merugu C prepared the first draft of the arthritis and the inflammatory bowel disease sections, respectively; Sahoo J, Naik D, and Kamalanathan S supervised the writing and critically revised the manuscript; Roy A, Sahoo J, and Kamalanathan S edited the final draft; all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: Dr. Sahoo has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jayaprakash Sahoo, MD, DM, Additional Professor, Department of Endocrinology, Jawaharlal Institute of Postgraduate Medical Education and Research, Room No. 5444, 4th Floor, Super Specialty Block, Puducherry 605006, India. jppgi@yahoo.com
Received: February 15, 2021
Peer-review started: February 15, 2021
First decision: March 30, 2021
Revised: April 12, 2021
Accepted: July 19, 2021
Article in press: July 19, 2021
Published online: September 15, 2021
Core Tip

Core Tip: Dipeptidyl peptidase-4 (DPP-4) has an important role in the function of the immune system. DPP-4 inhibitors are an important drug class for the management of type 2 diabetes mellitus. This group of drugs can have a diverse effect on immune modulation. Recently, certain autoimmune diseases are described with the use of DPP-4 inhibitors, particularly bullous pemphigoid. Clinicians should be aware of this association and take appropriate action if such an adverse event takes place.